Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
- Skin care
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 8452
Licensed IP Rights shall mean, collectively, all right, title and interest of Licensor or any of its Affiliates, as of the Effective Date or thereafter, in or to Patent Rights, Know-How Rights and other intellectual property rights in or to the Technology.
Prescription Drug Field shall mean the optimization, formulation and delivery of active pharmaceutical ingredients, and the development, manufacture and commercialization thereof in the prevention or treatment of any disease, state or condition in humans or other animals, in each case excluding compounding pharmacy activities.
Technology shall mean, collectively, all right, title and interest of Licensor or any of its Affiliates, as of the Effective Date or thereafter, in or to Drug Delivery Technology, Formulation Consulting Knowledge Base, Formulation Technology, and any other technology related to formulation or optimization of active pharmaceutical ingredients.
Formulation Consulting Knowledge Base shall mean all data an information relating to the formulation including topical, oral and suspension formulations of prescription drugs that is generated or derived by or on behalf of Licensor in connection with Licensor's consulting activities with or for Member/Customers, excluding data and information specific to Contract Formulations.
Drug Delivery Technology shall mean all inventions, discoveries, data, information, samples, and other technology relating to the delivery of active pharmaceutical ingredients.
IPSCIO Record ID: 338651
Licensor has technology called Liquitime that may be used for developing modified/controlled release oral pharmaceutical products in a liquid suspension formulation.
The patent is titled Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s).
The exclusive license includes Licensorâ€™s LiquiTimeÂ® Ibuprofen and LiquiTimeÂ® Guaifenesin oral suspensions; ibuprofen, an anti-inflammatory and Guaifenesin, an expectorant. These are the initial products.
IPSCIO Record ID: 279333
Intellectual Property means the Licensed Patents, the Licensor Know-How and the Licensor Technology.
Licensed Patents means Patents owned or controlled by Licensor or which Licensor, through license or otherwise, has or acquires rights, which are necessary or useful for the manufacture, use or sale of Licensed Product, including, but not limited to, compositions, formulations, methods of their manufacture, or methods of their use, or otherwise relate to Licensor Know-How or Licensor Technology, including (i) any of the Patents set forth hereto that contain claims that cover, or which relate to, any aspect of Licensed Product, (ii) the Development Patents and (iii) such other Patents as the Parties may agree in writing from time to time.
5,447,729 – Multilamellar drug delivery systems
5,484,608 – Sustained-release drug delivery system
Licensor Technology means Licensorâ€™s bioavailability enhancement and/ or controlled-release delivery, formulation, process and manufacturing technologies, including but not limited to the Licensor Lead Technology and the technologies embodied in the Licensed Patents and the Licensor Know-How.
Licensor Lead Technology means MicrotrolÂ® multi particulate technology or, as subsequently agreed between the Parties, one of the Other Licensor Technologies as may be applied to the Compound pursuant to the Development Plan.
Compound means trospium chloride, the chemical compound whose specific chemical name is 3-alpha benziloyJoxynortropane-8-spiro-1-pyrrolidinium; chloride, or any other trospium salt.
IPSCIO Record ID: 230783
Dapsone means 4,4 diaminodiphenylsulfone and all salts, polymorphs and isomers thereof.
Licensor Patent Rights or Licensor Patent means
5,863,560 – Compositions and Methods for Topical Application of Therapeutic Agents
6,060,085 – Compositions and Methods for Topical Application of Therapeutic Agents
09/236,909 (*pending application)
SMP(TM) technology or SMP(TM) delivery system means a technology and delivery system consisting of a combination of a dissolved drug with a microparticle suspension of the drug to allow a controlled amount of the dissolved drug to permeate the epidermal layer of the skin. The SMP(TM) technology includes, but is not limited to, topical formulations containing Dapsone.
Acne Product means the 3% Acne Product or the 5% Acne Product and any other concentrations of the Product that may be used for the treatment of acne vulgaris, depending on the decision of the JDMC.
IPSCIO Record ID: 256301
— an exclusive, even as to Licensor, worldwide license, with the right to sublicense, under the Licensor Technology, the Licensor Program Technology, and the Licensor Confidential Information and
— an exclusive, even as to Licensor, royalty-bearing worldwide sublicense, with a right of further sublicense, under the Licensed University Technology, in each case to make, have made, use, sell or import Licensed Products, Devices and Formulations in the Territory in the Field; and,
— an exclusive, even as to Licensor, worldwide license, with the right to sublicense, under the Licensor Patent Rights, and the Licensor Program Patent Rights and
— an exclusive, even as to Licensor, worldwide sublicense, with a right of further sublicense, under the Licensed University Patent Rights, in each case to make, have made, use, sell or import Licensed Products, Devices and Formulations in the Territory in the Field; and,
— a non-exclusive sublicense, without a right to further sublicense, to use the Licensor Trademarks with the Licensed Products, Devices and Formulations in the Territory in the Field.
Licensor has extensive expertise in designing and developing innovative ophthalmic drug delivery systems.
Medidur is a tiny injectable, non-erodible, intravitreal device for the treatment of Diabetic Macular Edema (DME), which can lead to blindness. The implant is injected into the back of the eye in an office setting rather than a surgical one. It releases a constant amount of drug and lasts between 18 to 36 months.
The Licensee's Compound means any composition of matter, including, small and large molecules, therapeutic proteins, polynucleotides, both double-stranded and singlestranded, and antibodies, or biosimilars.
Collaborative research and license agreement is for Licensorâ€™s controlled drug delivery technologies, including the MedidurTM technology, in ophthalmic applications.